AJP - Heart Ad Instruments
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Heart Circ Physiol 294: H1804-H1814, 2008. First published February 1, 2008; doi:10.1152/ajpheart.01078.2007
0363-6135/08 $8.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
294/4/H1804    most recent
01078.2007v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Phrommintikul, A.
Right arrow Articles by Krum, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Phrommintikul, A.
Right arrow Articles by Krum, H.

Effects of a Rho kinase inhibitor on pressure overload induced cardiac hypertrophy and associated diastolic dysfunction

Arintaya Phrommintikul,1,3,* Lavinia Tran,1,* Andrew Kompa,2,4 Bing Wang,1,2 Anastasia Adrahtas,1 Danielle Cantwell,1 Darren J. Kelly,4 and Henry Krum1,2

1Department of Epidemiology and Preventive Medicine, NHMRC Centre of Clinical Research Excellence in Therapeutics, 2Department of Medicine, Monash University, Melbourne; 4Department of Medicine, University of Melbourne, St. Vincent's Hospital, Melbourne, Australia; and 3Faculty of Medicine, Department of Internal Medicine, Chiang Mai University, Chiang Mai, Thailand

Submitted 17 September 2007 ; accepted in final form 30 January 2008


   ABSTRACT
TOP
 ABSTRACT
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
The RhoA-Rho kinase (ROCK) signaling pathway has an important role in cardiovascular diseases. However, the effect of Rho kinase inhibition on pressure overload-induced cardiac hypertrophy (POH) and associated diastolic dysfunction has not been evaluated. This study examined the effect of a selective ROCK inhibitor (GSK-576371) in a POH model, induced by suprarenal abdominal aortic constriction. POH rats were divided into the following four groups: 1 (GSK 1, n = 9) or 3 (GSK 3, n = 10) mg/kg bid GSK-576371, 1 mg·kg–1·day–1 ramipril (n = 10) or vehicle (n = 11) treatment for 4 wk. Sham animals (n = 11) underwent surgery without banding. Echocardiograms were performed before surgery and posttreatment, and hemodynamic data were obtained at completion of the study. Echocardiography showed an increase in relative wall thickness of the left ventricle (LV) following POH + vehicle treatment compared with sham animals. This was attenuated by both doses of GSK-576371 and ramipril. Vehicle treatment demonstrated abnormal diastolic parameters, including mitral valve (MV) inflow E wave deceleration time, isovolumic relaxation time, and MV annular velocity, which were dose dependently restored toward sham values by GSK-576371. LV end diastolic pressure was increased following POH + vehicle treatment compared with sham (6.9 ± 0.7 vs. 3.2 ± 0.7 mmHg, P = 0.008) and was reduced with GSK 3 and ramipril treatment (1.7 ± 0.7, P < 0.01 and 2.9 ± 0.6 mmHg, P < 0.01, respectively). Collagen I deposition in the LV was increased following POH + vehicle treatment (32.2%; P < 0.01) compared with sham animals and was significantly attenuated with GSK 1 (21.7%; P < 0.05), GSK 3 (23.8%; P < 0.01), and ramipril (35.5%; P < 0.01) treatment. These results suggest that ROCK inhibition improves LV geometry and reduces collagen deposition accompanied by improved diastolic function in POH.

Rho kinase; hypertrophy; fibrosis; pressure overload; hypertension; diastolic function; myocardium

HEART FAILURE IS a major health problem. Cardiac hypertrophy with or without hypertension is one of the major antecedent pathological changes associated with heart failure (2, 7, 10, 24). In turn, attenuation of cardiac hypertrophy has been a major focus of intervention to prevent both systolic and diastolic heart failure. In addition to cardiac hypertrophy, both forms of heart failure are also associated with increased fibrosis.

The RhoA-Rho kinase (ROCK) signaling pathway has been demonstrated to have an important role in cardiovascular disease states. Activation of Rho kinase is initiated by the binding of a low-molecular-weight G protein Rho to the Rho-binding domain on the COOH terminal (16, 33). Activated Rho kinase can phosphorylate downstream targets thought to be involved in remodeling. Myosin light chain phosphatase (MLCP) is one such target. Once phosphorylated, the MLCP enzyme is inhibited, thereby stimulating vascular smooth muscle contraction, stress fiber formation, and cell migration (16, 33).

These effects contribute to diastolic dysfunction, most notably by processes involving inflammatory cell infiltration, adhesion to the endothelium, and activation of fibroblasts into myofibroblasts, thereby initiating fibrosis (17, 33). Furthermore, Rho kinase mediates upregulation of proinflammatory cytokines and mediators such as interleukin-6, monocyte chemoattractant protein-1, and transforming growth factor-β1. Hence activation of Rho kinase accelerates inflammation and tissue fibrosis, both important processes involved in the pathophysiology of diastolic heart failure (33). Diastolic dysfunction and failure is a common clinical condition, frequently occurring in pressure overload settings such as systemic hypertension (11, 27). Treatment of diastolic heart failure is currently empirical, since no class of agent has yet been demonstrated to favorably impact clinical outcomes. Thus novel therapies in this setting are urgently required.

Fukui et al. (8) has reported activation of Rho kinase in diastolic dysfunction, demonstrating that this pathway may indeed represent such a novel target. Rho kinase inhibition with fasudil attenuates ANG II-induced cardiac hypertrophy and fibrosis (14, 39), and, in Dahl salt-sensitive rats, ventricular hypertrophy and fibrosis are ameliorated by ROCK inhibition with Y-27632 (23). ROCK1 knockout mice exhibited reduced myocardial fibrosis in transverse aortic-banded animals and ANG II-induced hypertension, without effects on cardiac hypertrophy (5, 42).

Animal models of diastolic dysfunction, such as acute and chronic pressure overload, recapitulate the diastolic dysfunction phenotype (14, 23, 36, 42). The effect of pharmacological Rho kinase inhibition on pressure overload-induced cardiac hypertrophy (POH) and its associated diastolic dysfunction has not been previously evaluated. Therefore, this study aimed to determine the effect of a selective ROCK inhibitor (GSK-576371) on POH and diastolic function, as carefully assessed using echocardiographic, hemodynamic, immunohistochemical, and molecular methodologies.


   MATERIALS AND METHODS
TOP
 ABSTRACT
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Animal Preparation

POH was induced by suprarenal abdominal aortic constriction using male Sprague-Dawley (SD) rats (180–230 grams). The abdominal aorta was constricted with a 4–0 silk tie around a blunt 21-gauge probe (0.8 mm outer diameter) just above the right renal artery. The probe was promptly removed after constriction. Sham operation was performed in the same manner, but the abdominal aorta was not constricted. The POH rats received a highly selective Rho kinase inhibitor, GSK-576371, at 1 mg/kg (GSK 1) and 3 mg/kg (GSK 3) two times daily or vehicle treatment. Ramipril (1 mg/kg) one time daily serves as a positive control. All treatments were given by oral gavage and commenced 24 h postsurgery for a period of 4 wk. All animal procedures outlined in this study were approved for use by the St. Vincent's Hospital Animal Ethics Committee in accordance with the National Health and Medical Research Council of Australia guidelines.

Drugs

Rho kinase inhibitor GSK-576371 was a gift from GlaxoSmithKline (King of Prussia, PA). Ramipril (Aventis, Lane Cove, NSW), a commercially available and widely used angiotensin-converting enzyme inhibitor was purchased from the Alfred Hospital Pharmacy. Both GSK-576371 and ramipril were administered by oral gavage in 0.5% methylcellulose (vehicle) solution.

Assessment of Cardiac Hypertrophy and Function by Echocardiography

Echocardiography was performed at baseline (1 day before surgery) and at the end of study under light anesthesia with ketamine and xylazine (40 and 5 mg/kg ip, respectively) using a Vivid 7 (GE Vingmed, Horten, Norway) echocardiographic machine with a 10-MHz phased array probe. The procedure was performed as per published standard protocol (6). Parasternal short-axis views of the heart at the midpapillary level were used to obtain measures of the interventricular septal (IVSd) and posterior wall thickness (LVPWd) in diastole, and left ventricular internal dimension in diastole and systole. Percentage fractional shortening (%FS) and relative wall thickness (RWT) were calculated according to standard formulas (31). Doppler images were obtained from the apical four-chamber view of the heart as previously described in the standard protocol (6). Early and late transmitral peak diastolic flow velocity (E and A waves), mitral valve (MV) inflow E wave deceleration time (DT), and isovolumic relaxation time (IVRT) were measured. Tissue Doppler imaging was performed from the apical four-chamber view and used to assess peak early and late (E' and A') diastolic tissue velocity at the septal side of the mitral annulus. The data were obtained for all rats using a dedicated rodent software package. Trans-stenotic pressure gradient was recorded at 1 wk and at the end of the study in the POH group. POH animals with trans-stenotic pressure gradient >50 mmHg were used in the analysis. All parameters were assessed using an average of three beats, and calculations were made in accordance with the American Society of Echocardiography guidelines (31). All data were acquired and analyzed by a single blinded observer using Echo PAC (GE Vingmed) offline processing.

Hemodynamic Parameters

Hemodynamic data were obtained at the end of the study under anesthesia with Nembutal (60 mg/kg) as per published standard protocol (6). Animals were ventilated, and a 2-Fr miniaturized combined catheter-micromanometer (Model SPR-838; Millar instruments, Houston, TX) was inserted in the right common carotid artery to obtain aortic blood pressure and then advanced in the LV to obtain left ventricular pressure-volume (PV) loops. PV loops were recorded at steady state and during transient preload reduction, achieved by transient occlusion of the inferior vena cava and portal vein with the ventilator turned off and the animal apnoeic. The following validated parameters were assessed using Millar conductance data acquisition and analysis software PVAN 3.2: left ventricular end systolic pressure, left ventricular end diastolic pressure (LVEDP), the slope of the end systolic pressure volume relationship, the slope of the end diastolic pressure volume relationship, maximum and minimum dP/dt (mmHg/s), Tau ({tau} Logistic), and the slope of the preload recruitable stroke work relationship.

Histological Analysis

At the end of the study, the heart and lungs were harvested, and dried weights were recorded. Transverse sections of the heart were fixed in Tissue-Tek optimum-cutting temperature (OCT)-embedding compound (Sakura Finetek, Chuo-ku, Tokyo, Japan) for histology or frozen with liquid nitrogen for subsequent molecular analyses.

Measurement of Myocyte Cross-sectional Area

Tissue-Tek OCT-embedded tissues were stained with hematoxylin/eosin. The perimeters of 50 myocytes from each animal were traced and analyzed as previously described (32). These data were used to calculate the myocyte mean cross-sectional area in each animal.

Immunoreactivity Analyses for Collagen Type I and III in Left Ventricular Tissue

Tissue-Tek OCT-embedded tissues were cut and mounted on poly-L-lysine (Sigma Diagnositcs, St Louis, MO)-coated slides. Serial sections were stained with a three-layer immunoperoxidase technique for collagen type I and collagen type III and quantitatively assessed by a single blinded researcher as previously described (37). Results were expressed as average percentage area of 10 random fields for each section.

Quantitative mRNA Expression in Left Ventricular Tissue

Total RNA was extracted from frozen cardiac tissues using RNAeasy columns (Qiagen, Hilden, Germany) and reverse transcribed to cDNA with MultiScribe. Triplicate cDNA aliquots (0.5 ng each) were amplified using sequence-specific primers (Geneworks, Adelaide, SA, Australia) and a TaqMan fluorogenic probe (Applied Biosystems, Foster City, CA) using an ABI prism 7900HT sequence Detection System (Applied Biosystems). RT-PCR was used to quantify cardiac gene expression of procollagen {alpha}1(I) and connective tissue growth factor (CTGF). The primer pairs and probes were designed using Primer Express 2.0 software (Applied Biosystems) based on published sequences (http://www.ncbi.nlm.nih.gov) as previously described (22). 18S rRNA was used as an endogenous control in all experiments to correct for the expression of each gene.

In Vitro Studies

Neonatal rat cardiomyocytes and fibroblast cultures. Neonatal SD rat cardiac myocytes (NCMs) and fibroblasts (NCFs) were isolated from 1-day-old pups with enzymatic digestion as described in detail previously (34, 40). NCFs were seeded and maintained in high-glucose (25 mmol/l) DMEM (Invitrogen Mount Waverley, Vic, Australia) in the presence of 1% antibiotic/antimycotic and 10% FBS (JRH biosciences). NCFs were used at passage 2 (32). Purified NCMs were seeded (1,000 cells/mm2) in six-well plates and maintained in serum-free DMEM (Invitrogen) supplemented with insulin and transferrin as described previously (40). Bromodeoxyuridine was included for the first 3 days. KCl (50 mmol/l) was added to the medium to prevent spontaneous contraction characteristic of the plated NCMs (35).

Measurement of neonatal rat cardiomyocyte hypertrophy. NCM hypertrophy studies were performed as previously described (35). Four hours after treatment with the Rho kinase inhibitor (10–7 to 10–5 mol/l GSK-576371), ANG II (10–7 mol/l) was used to stimulate hypertrophy. After 60 h of stimulation, cells were harvested, and hypertrophy was defined as a significant increase in protein content (Bradford assay) in the absence of any significant change in DNA content (Burton assay; see Ref. 35). Control cells were not preincubated with GSK and were not stimulated with ANG II.

Measurement of collagen synthesis, proliferation, and cell viability in neonatal rat cardiac fibroblasts. NCF collagen synthesis assays were performed as described previously (32). NCFs were plated at a density of 25,000 cells/well in 12-well plates and incubated (5% CO2) overnight. NCFs were then serum starved for 48 h in high-glucose DMEM. The cells were then preincubated for 30 min in the presence or absence of GSK-576371 (10–7 to 10–5 mol/l) in fresh DMEM-F1–2 before stimulation with 2 x 10–10 mol/l of transforming growth factor (TGF)-β1 or 10–7 mol/l of ANG II.

For collagen synthesis, 1 µCi of [3H]proline was added to each well and incubated for a further 48 h before harvest. Cells were harvested by precipitation with 10% TCA on ice for 30 min before solubilization with 0.75 ml of 1 mol/l NaOH overnight at 4oC. The samples were then neutralized with 1 mol/l HCl, and 3H levels were counted with 10 ml scintillation fluid on a beta counter to determine the levels of [3H]proline incorporation.

For proliferation studies, NCFs were treated with 1 µCi of [3H]thymidine to each well 2 h before harvesting. Cells were harvested by TCA precipitation as described for collagen synthesis above to determine the levels of [3H]thymidine incorporation.

Statistical Analysis

Data are reported as means ± SE. Comparisons between groups were analyzed by one-way ANOVA followed by Bonferroni's post hoc t-test as appropriate. Two-sided P < 0.05 was considered statistically significant. Dose-dependent effects of Rho kinase inhibition were determined by Tukey trend test. This test is applicable when considering the same drug in the same setting at three or more different dosages (i.e., 0, 1, and 3 mg GSK-576371; see Ref. 1).


   RESULTS
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 GRANTS
 REFERENCES
 
From 43 POH rats, two were excluded from the study due to trans-stenotic pressure gradient <50 mmHg.

Mortality

Survival rate was 100% in sham animals as well as in POH animals receiving all active treatments and 91.7% in POH with vehicle treatment (P > 0.05).

Echocardiographic Measurements

Baseline echocardiographic findings were not different between groups (Table 1). At the end of 4 wk, there was a significant increase in diastolic wall thicknesses (IVSd and LVPWd) and RWT in the POH + Vehicle group compared with sham. RWT increased by 61.6% (P < 0.001) in the POH + Vehicle group compared with sham. GSK 1 and 3 and ramipril treatment significantly attenuated RWT by 24.7% (P < 0.01), 26.0% (P < 0.001) and 20.2% (P < 0.05), respectively, from POH + Vehicle levels (Fig. 1). Left ventricle (LV) cavity size was not significantly different in all groups. LV mass was significantly increased by 27% (P < 0.01) in POH + vehicle animals. There was a dose-dependent decrease with GSK 1 and GSK 3 upon trend test, supporting an antihypertrophic effect of the agent (Table 2 and Fig. 2).


View this table:
[in this window]
[in a new window]

  		Table 1. Baseline echocardiographic data

 

Figure 1
View larger version (11K):
[in this window]
[in a new window]

  		Fig. 1. Relative wall thickness (RWT) of the left ventricle. RWT is significantly increased by 61.6% in the pressure overload-induced cardiac hypertrophy (POH) + Vehicle group compared with shams. This increase was dose dependently reduced with 1 (GSK 1) and 3 (GSK 3) mg/kg bid GSK-576371 treatments. Ramipril treatment also demonstrated a decrease in RWT. ***P < 0.001 vs. sham. #P < 0.05, ##P < 0.01, and ###P < 0.001 vs. POH + vehicle (n = 9–11 experiments).

 

View this table:
[in this window]
[in a new window]

  		Table 2. Echocardiographic data at 4 wk

 

Figure 2
View larger version (66K):
[in this window]
[in a new window]

  		Fig. 2. M-mode images representing left ventricle (LV) dimensions. A: 2-dimensional M-mode echocardiography image defining the following LV parameters: interventricular septum in diastole (IVSd), left ventricular posterior wall in diastole (LVPWd), left ventricular internal dimension at diastole (LVIDd), and left ventricular internal dimension in systole (LVIDs). B-F: representative echocardiograms from each group demonstrating changes in wall thickness.

 
Systolic function measured by FS was preserved in all groups; however, FS was higher in high-dose GSK-567371 treatment compared with sham animals but not different compared with the other POH groups.

There were significant changes in parameters of diastolic function in POH rats measured at 4 wk. MV DT and IVRT were prolonged in POH rats receiving vehicle treatment compared with sham animals. GSK-576371 reduced these parameters in a dose-dependent manner and restored them to sham values with GSK high-dose therapy (Fig. 3). Ramipril did not have any significant effect on diastolic parameters (Table 2).


Figure 3
View larger version (11K):
[in this window]
[in a new window]

  		Fig. 3. Parameters of diastolic function. A: deceleration time (DT) was significantly increased in POH + Vehicle group compared with sham. GSK 3 treatment significantly reduced DT. B: isovolumic relaxation time (IVRT) as significantly increased in the POH + Vehicle group compared with shams. GSK 3 treatment significantly reduced IVRT. P < 0.001 vs. sham (***) and vs. POH + Vehicle (###).

 
Hemodynamic Measurements

Systolic blood pressure was elevated by 35 mmHg in vehicle-treated POH rats compared with sham animals (P = 0.018) (Table 3). Treatment with GSK-576371 and ramipril did not have any significant effect on systolic blood pressure. Furthermore, diastolic blood pressure and mean arterial blood pressure were not different between groups (Table 3). Pulse pressure was, however, significantly higher in POH + Vehicle rats compared with sham animals, and 3 mg/kg bid GSK-576371 attenuated this pressure toward sham values (Table 3).


View this table:
[in this window]
[in a new window]

  		Table 3. Hemodynamic data at 4 wk

 
LVEDP was more than twofold elevated in POH rats receiving vehicle treatment compared with sham animals (6.9 ± 0.7 vs. 3.2 ± 0.7 mmHg, P = 0.008), and GSK 576371 lowered LVEDP dose dependently. Similarly, ramipril significantly reduced LVEDP (Table 3).

There was a significant correlation between diastolic parameters from echocardiogram and LVEDP in all groups. Both IVRT (r = 0.514, P = 0.001) and MV inflow DT (r = 0.376, P = 0.015) were positively correlated with LVEDP.

Heart and Body Weight

Body weight was not different between groups at the end of the study. Heart weight and the ratio of heart weight to body weight were significantly increased by 20.6 and 19.3%, respectively, in the POH rats receiving vehicle treatment compared with sham (P < 0.01) (Table 4).


View this table:
[in this window]
[in a new window]

  		Table 4. Organ weight

 
Myocyte Size

Myocyte cross-sectional area was significantly increased in POH + Vehicle treatment by 22.5% (416.6 ± 28.1 µm2) compared with sham animals (298.4 ± 16.8 µm2) (P < 0.05). GSK 1 and 3 and ramipril treatment did not significantly reduce myocyte size (411.6 ± 27.8, 337.2 ± 8.8, and 386.7 ± 17.7 µm2, respectively) compared with POH + Vehicle animals (Fig. 4).


Figure 4
View larger version (11K):
[in this window]
[in a new window]

  		Fig. 4. Myocyte cross-sectional area increased in POH + Vehicle animals compared with sham animals. This was nonsignificantly attenuated with high-dose GSK-576371 treatment (POH + GSK 3) compared with POH + Vehicle treatment (n = 9–11). **P < 0.01 vs. sham (n = 11).

 
Collagen Expression in Left Ventricular Tissue

Immunohistochemistry. An increase in collagen type I deposition in POH + Vehicle rats by 34.5% (P < 0.01) compared with sham animals was observed; this was reduced with GSK 1 and GSK 3 and ramipril treatment by 21.7% (P < 0.05), 23.8% (P < 0.01), and 35.5% (P < 0.01), respectively (Table 5 and Fig. 5). No change in collagen III was detected among all groups (Table 5).


View this table:
[in this window]
[in a new window]

  		Table 5. Left ventricular immuno-reactivity data for collagen

 

Figure 5
View larger version (99K):
[in this window]
[in a new window]

  		Fig. 5. Representative immunoreactivity of collagen I in the LV of each group. Magnification x200. A–E: collagen I immunoreactivity was increased in the POH + Vehicle group by 34.5% (P < 0.01) compared with sham animals. This increase was completely inhibited by treatment with GSK 1, GSK 3, and rampiril. GSK 1 reduced collagen deposition by 21.7% (P < 0.05), GSK 3 by 23.8% (P < 0.01), and ramipril by 35.5% (P < 0.01) with respect to the POH + Vehicle group.

 
Tissue levels of collagen I were moderately correlated to LVEDP (r = 0.324, P = 0.054).

Real-time PCR. The increase in procollagen {alpha}1(I) and CTGF gene expression after 4 wk was not statistically significant in POH + Vehicle-treated rats vs. sham (Fig. 6). Similarly, reductions in expression of these genes with active therapy did not reach statistical significance.


Figure 6
View larger version (11K):
[in this window]
[in a new window]

  		Fig. 6. Gene expression in the LV. A: procollagen {alpha}(I) gene expression was nonsignificantly increased in the LV. B: connective tissue growth factor (CTGF) gene expression was nonsignificantly increased in the POH + Vehicle group compared with shams.

 
In Vitro Studies

Effects of Rho kinase inhibition on cardiomyocyte hypertrophy in isolated neonatal rat cardiomyocytes. ANG II-stimulated cardiomyocytes produced a 25.8% increase in hypertrophy compared with unstimulated cells (P < 0.001). GSK-576371 reduced ANG II-stimulated cardiomyocyte hypertrophy in a dose-dependent manner (Fig. 7A). NCM were unchanged with GSK alone treatment, indicating GSK did not induce NCM hypertrophy (Fig. 7B).


Figure 7
View larger version (10K):
[in this window]
[in a new window]

  		Fig. 7. Effects of GSK-576371 on neonatal cardiac myocytes (NCM). A: GSK-576371 dose dependently inhibited ANG II-induced NCM hypertrophy. B: GSK-576371 alone did not have any effect on NCM hypertrophy. *P < 0.05 and **P < 0.01 vs. ANG II stimulation. Results are expressed as a percentage of control (unstimulated cells) at 100% (n = 3).

 
Effects of Rho Kinase Inhibition on Cell Proliferation and Collagen Synthesis in Isolated Cardiac Fibroblasts

Both ANG II and TGF-β1 increased collagen synthesis in rat cardiac fibroblasts by 109% (P < 0.01) and 116% (P < 0.01), respectively, as determined by [3H]proline incorporation. GSK-576371 reduced both ANG II- and TGF-β1-stimulated collagen synthesis in a dose-dependent manner compared with stimulant alone (Fig. 8, A and B, respectively).


Figure 8
View larger version (20K):
[in this window]
[in a new window]

  		Fig. 8. Effect of GSK-576371 on neonatal cardiac fibroblasts (NCF). A and B: GSK-576371 (10–7 to 10–5 mol/l) inhibited ANG II- and transforming growth factor (TGF)-β1-induced proline incorporation in NCF. C and D: GSK-576371 (10–7 to 10–5 mol/l) inhibited ANG II- and TGF-β1-induced thymidine incorporation in NCF. *P < 0.05 and **P < 0.01 vs. control (ANG II or TGF-β1). Results are expressed as a percentage of control (unstimulated cells) at 100% (n = 5).

 
Similarly, ANG II and TGF-β1 increased cell proliferation in rat cardiac fibroblasts by 57% (P < 0.01) and 111% (P < 0.01), respectively, as determined by [3H]thymidine incorporation. GSK-576371 reduced both ANG II- and TGF-β1-stimulated cell proliferation in a dose-dependent manner compared with stimulant alone (Fig. 8, C and D, respectively).


   DISCUSSION
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
GRANTS
 REFERENCES
 
Heart failure with preserved systolic function (HFPSF) is highly prevalent in the community and associated with significant morbidity and mortality (15, 38). HFPSF is characterized by prolonged myocardial relaxation and abnormal tissue stiffness (43). The major etiological factor for this condition is systemic hypertension, a comorbid risk factor observed in >25% of the adult population in the Western world (3, 18). Abrogation of these abnormalities has been a major therapeutic target in heart failure management. In the present study, we used a well-validated animal model of diastolic dysfunction that is the cornerstone of HFPSF to study the contribution of the ROCK signaling pathway to this condition. Diastolic dysfunction is of uncertain clinical relevance however is clearly a harbinger of HFPSF. This is, to our knowledge, the first study to examine the pharmacological effects of Rho kinase blockade in diastolic dysfunction, carefully evaluating cardiac function using echocardiographic (including tissue Doppler imaging), hemodynamic, immunohistochemical, and molecular techniques. These data complement and further extend our knowledge base in this area, as generated initially by genetic models of RhoA/Rho kinase system knockout. These genetic model studies demonstrated reduced cardiac fibrosis and variable effects on cardiac hypertrophy. Thus two quite different approaches to blockade of the RhoA/Rho kinase system have yielded similar data with regard to the pathophysiological and therapeutic relevance of blockade of this system.

As expected, suprarenal aortic banding-induced POH was accompanied by diastolic dysfunction with preserved ejection fraction. Rho kinase inhibition by GSK-576371 dose dependently attenuated increased left ventricular wall thickness (IVS and LVPW), thereby reducing RWT and consequently improving diastolic function in rats with POH.

DT, IVRT, and LVEDP were all restored toward sham values by GSK-576371 and ramipril treatment. This was accompanied by a decrease in myocardial fibrosis (reduced collagen I deposition) with GSK-576371 treatment. The significant improvement in LV geometry and diastolic function with GSK-576371 occurred without significant changes in systolic blood pressure and mean arterial blood pressure, although pulse pressure was significantly lower with high-dose GSK-576371 treatment. Pulse pressure is a significant independent predictor of future cardiovascular events in major epidemiological cohorts such as the Framingham study (12). Mechanistically, pulse pressure may reflect aortic compliance; this may have been beneficially affected with the Rho kinase inhibitor. However, in the present study, we did not examine aortas from a functional or histopathological viewpoint. This would be an important component of further study with this class of agent. Furthermore, heart rate was significantly increased with high-dose GSK-576371 in our hemodynamic studies, making interpretation of diastolic parameters difficult.

The in vivo cardiac effects observed in the present study may represent a direct effect of Rho kinase inhibition upon the myocardium as suggested by the in vitro data. Nevertheless, there was also the previously noted reduction in systemic blood pressure, almost certainly reflecting the impact of Rho kinase inhibition on vascular tone. This does cloud the ability to determine direct vs. indirect effects of the active therapy on myocardial function in vivo. The accompanying in vitro studies are therefore of considerable assistance in this regard. It would be of interest to study Rho kinase inhibition at lower nonhemodynamic doses, but these doses may also be too low to observe direct cardiac effects. In any event, from a purely therapeutic prospective, the beneficial cardiac effects mediated by Rho kinase inhibition upon the myocardium (be they direct or indirect) may represent a potentially useful therapeutic approach, complementary to existing drug strategies.

LV geometry is a major predictor of morbidity and mortality in uncomplicated hypertension. Hypertensive patients with concentric LV hypertrophy (LVH) exhibit a higher morbidity and mortality than those with eccentric LVH (20). Previous studies have found that RWT along with LV mass are important parameters used to classify concentric and eccentric hypertrophy (9, 20). Treatment with GSK-576371 significantly decreased RWT in POH rats, reflecting a geometric alteration toward eccentric hypertrophy. Altering LV geometry from concentric to eccentric hypertrophy may be an important mechanism underlying improved diastolic function with Rho kinase inhibition. Similar findings have been observed with angiotensin receptor blockers on diastolic function in hypertensive patients (26).

Extracellular matrix remodeling in POH has been demonstrated to be an important contributor to diastolic and eventual systolic dysfunction (4, 5, 28). There is emerging evidence suggesting that increased myocardial fibrosis is a major factor responsible for myocardial stiffness and may be more important than myocyte hypertrophy (17, 21, 41). The present study demonstrated increased collagen I deposition in the LV of POH rats that had a moderate degree of correlation with LVEDP. Treatment with GSK-576371 had significant beneficial effects on extracellular remodeling, with a reduction in collagen I protein in the LV of POH rats.

Attenuation of myocardial fibrosis by GSK-576371 may be a major mechanism associated with the improvement in diastolic function in POH rats. In our in vitro study, the direct effect of GSK-576371 on cardiac collagen turnover was examined in ANG II- and TGF-β1-stimulated cardiac fibroblasts, with a decrease observed in collagen synthesis and cell proliferation. However, because gene expression of collagen I and CTGF is not significantly increased in vivo in POH + Vehicle animals compared with sham, it is somewhat difficult to further interpret the antifibrotic effect of GSK-576371 from these data.

Rho kinase inhibition with fasudil has been shown to reduce cardiac fibrosis in postmyocardial infarction animals, spontaneously hypertensive rats, and in an ANG II infusion model of cardiac hypertrophy (13, 14, 25). Inhibition of Rho kinase by ROCK1 gene deletion also reduced myocardial fibrosis in animals with transverse aortic banding as well as in ANG II-induced hypertension compared with the wild type (29, 42).

Our study showed that Rho kinase inhibition by GSK-576371 attenuated myocardial fibrosis, accompanied by a significant dose-dependent reduction in LV mass on echocardiography. This was paralleled by a dose-dependent reduction in heart weight with GSK-576371 treatment. Previous studies have reported that Rho kinase inhibition with fasudil attenuated both cardiac fibrosis and hypetrophy in ANG II-induced cardiac hypertrophy (14, 39). Treatment with Y-27632 has demonstrated an attenuation of myocardial hypertrophy both with and without beneficial effects on myocardial fibrosis in Dahl salt-sensitive rats (19, 30). In contrast, ROCK1 knockout mice exhibited reduced myocardial fibrosis in transverse aortic-banded animals and ANG II-induced hypertension, without effects on cardiac hypertrophy (29, 42).

Rho kinase exists as two isoforms, ROCK1 and ROCK2. It may be that, as alluded to by Zhang et al. (42), ROCK1 plays an important role in the development of pathological fibrosis, and ROCK2 is involved in the development of hypertrophy. Furthermore, the effects of Rho kinase inhibition on cardiac hypertrophy may depend on the degree of hypertrophy developed in a particular animal model. Attenuation of cardiac hypertrophy with Rho kinase inhibition occurs in hypertensive animals that exhibit a >50% increase in hypertrophy compared with their control group (14, 19, 39). In contrast, the degree of hypertrophy was only 10% in a study that did not show a reduction with Rho kinase inhibition (29). In the present in vivo study, an increase in hypertrophy was observed, which was significantly reduced with GSK treatment. Specifically, there was a significant dose-dependent reduction in LV mass on echocardiography as well as a nonsignificant reduction in the heart rate-to-body weight ratio at high doses of GSK-576371. Furthermore, our in vitro study demonstrated that GSK-576371 significantly inhibited ANG II-induced neonatal rat cardiomyocyte hypertrophy.

Rho Kinase Inhibitor Specificity

The agent used in the present study, GSK-576371, nonselectively inhibits both ROCK1 and ROCK2. GSK-576371 is >50–1,000 fold more selective for ROCK than other serine/threonine kinases, and it inhibits Rho kinase in the low nanomolar range (personal communication, Robert J Willette, GlaxoSmithKline, King of Prussia, PA). In comparison, other Rho kinase inhibitors (Fasudil and Y-27632) are effective in the micromolar range (33).

In summary, Rho kinase inhibition with GSK-576371 improved LV geometry and reduced collagen deposition in a rat POH model of diastolic dysfunction. Improvements in LV geometry and reduction of myocardial fibrosis may be important mechanisms that underlie the beneficial effects of this agent on diastolic function. Based on the above considerations, Rho kinase inhibition may represent a novel therapeutic approach to the treatment of diastolic dysfunction and accompanying HFPSF.


   GRANTS
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
REFERENCES
 
We acknowledge support from the National Health and Medical Research Council Program Grants 334008 and 11079 and the Heart Foundation of Australia (G 06M 2644).


   ACKNOWLEDGMENTS
 
We thank GlaxoSmithKline for kindly providing the drug GSK 576371.


   FOOTNOTES
 

Address for reprint requests and other correspondence: H. Krum, NHMRC Centre of Clinical Research Excellence in Therapeutics, Dept. of Epidemiology & Preventive Medicine, Monash Univ./Alfred Hospital, Melbourne VIC 3004, Australia (e-mail: henry.krum{at}med.monash.edu.au)

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

* A. Phrommintikul and L. Tran contributed equally to this work. Back


   REFERENCES
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 

  1. Antonello JM, Clark RL, Heyse JF. Applicaton of the Tukey trend test procedure to assess developmental and reproductive toxicity. Toxicol Sci 21: 52–58, 1993.[Abstract/Free Full Text]
  2. Aronow WS, Ahn C. Association of electrocardiographic left ventricular hypertrophy with the incidence of new congestive heart failure. J Am Geriatr Soc 46: 1280–1281, 1998.[Web of Science][Medline]
  3. Briganti EM, Shaw JE, Chadban SJ, Zimmet PZ, Welborn TA, McNeil JJ, Atkins RC. Untreated hypertension among Australian adults: the 1999–2000 Australian Diabetes, Obesity and Lifestyle Study (AusDiab). Med J Aust 179: 135–139, 2003.[Web of Science][Medline]
  4. Brilla CG, Maisch B, Weber KT. Myocardial collagen matrix remodelling in arterial hypertension. Eur Heart J 13, Suppl D: 24–32, 1992.
  5. Brilla CG, Reams GP, Maisch B, Weber KT. Renin-angiotensin system and myocardial fibrosis in hypertension: regulation of the myocardial collagen matrix. Eur Heart J 14, Suppl J: 57–61, 1993.[Abstract/Free Full Text]
  6. Connelly KA, Prior DL, Kelly DJ, Feneley MP, Krum H, Gilbert RE. Load-sensitive measures may overestimate global systolic function in the presence of left ventricular hypertrophy: a comparison with load-insensitive measures. Am J Physiol Heart Circ Physiol 290: H1699–H1705, 2006.[Abstract/Free Full Text]
  7. Drazner MH, Rame JE, Marino EK, Gottdiener JS, Kitzman DW, Gardin JM, Manolio TA, Dries DL, Siscovick DS. Increased left ventricular mass is a risk factor for the development of a depressed left ventricular ejection fraction within five years: the Cardiovascular Health Study. J Am Coll Cardiol 43: 2207–2215, 2004.[Abstract/Free Full Text]
  8. Fukui S, Fukumoto Y, Suzuki J, Saji K, Nawata J, tawara s Shinoazaki T, Kagaya Y, Shimokawa H. The important role fo Rho-kinase Pathway in the pathogenesis of diastolic heart failure in rats (abstract). J Card Fail 13: 008, 2007.[CrossRef]
  9. Ganau A, Devereux R, Roman M, Simone Gd Pickering T, Saba P, Vargiu P, Simongini I, Laragh J. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J Am Coll Cardiol 19: 1550–1558, 1992.[Abstract]
  10. Gardin JM, McClelland R, Kitzman D, Lima JA, Bommer W, Klopfenstein HS, Wong ND, Smith VE, Gottdiener J. M-mode echocardiographic predictors of six- to seven-year incidence of coronary heart disease, stroke, congestive heart failure, and mortality in an elderly cohort (the Cardiovascular Health Study). Am J Cardiol 87: 1051–1057, 2001.[CrossRef][Web of Science][Medline]
  11. Gerard PA. Diastolic heart failure: a common and lethal condition by any name (Abstract). New Engl J Med 355: 308, 2006.[Free Full Text]
  12. Haider AW, Larson MG, Franklin SS, Levy D. Systolic blood pressure, diastolic blood pressure, and pulse pressure as predictors of risk for congestive heart failure in the Framingham Heart Study. Ann Intern Med 138: 10–16, 2003.[Abstract/Free Full Text]
  13. Hattori T, Shimokawa H, Higashi M, Hiroki J, Mukai Y, Tsutsui H, Kaibuchi K, Takeshita A. Long-term inhibition of Rho-kinase suppresses left ventricular remodeling after myocardial infarction in mice. Circulation 109: 2234–2239, 2004.[Abstract/Free Full Text]
  14. Higashi M, Shimokawa H, Hattori T, Hiroki J, Mukai Y, Morikawa K, Ichiki T, Takahashi S, Takeshita A. Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo: effect on endothelial NAD(P)H oxidase system. Circ Res 93: 767–775, 2003.[Abstract/Free Full Text]
  15. Hogg K, Swedberg K, McMurray J. Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol 43: 317–327, 2004.[Abstract/Free Full Text]
  16. Jalil J, Lavandero S, Chiong M, Paz Ocaranza M. Rho/Rho kinase signal transduction pathway in cardiovascular disease and cardiovascular remodeling. Rev Espan Cardiol 58: 951–961, 2005.
  17. Kai H, Kuwahara F, Tokuda K, Imaizumi T. Diastolic dysfunction in hypertensive hearts: roles of perivascular inflammation and reactive myocardial fibrosis. Hypertens Res 28: 483–490, 2005.[CrossRef][Web of Science][Medline]
  18. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 365: 217–223, 2005.[Web of Science][Medline]
  19. Kobayashi N, Horinaka S, Mita S, Nakano S, Honda T, Yoshida K, Kobayashi T, Matsuoka H. Critical role of Rho-kinase pathway for cardiac performance and remodeling in failing rat hearts. Cardiovasc Res 55: 757–767, 2002.[Abstract/Free Full Text]
  20. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 114: 345–352, 1991.[Abstract/Free Full Text]
  21. Kuwahara F, Kai H, Tokuda K, Takeya M, Takeshita A, Egashira K, Imaizumi T. Hypertensive myocardial fibrosis and diastolic dysfunction: another model of inflammation? Hypertension 43: 739–745, 2004.[Abstract/Free Full Text]
  22. Martin J, Denver R, Bailey M, Krum H. In vitro inhibitory effects of atorvastatin on cardiac fibroblasts: implications for ventricular remodelling. Clin Exp Pharmacol Physiol 32: 697–701, 2005.[CrossRef][Web of Science][Medline]
  23. Mita S, Kobayashi N, Yoshida K, Nakano S, Matsuoka H. Cardioprotective mechanisms of Rho-kinase inhibition associated with eNOS and oxidative stress-LOX-1 pathway in Dahl salt-sensitive hypertensive rats. J Hypertens 23: 87–96, 2005.[CrossRef][Web of Science][Medline]
  24. Moser M, Hebert PR. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. J Am Coll Cardiol 27: 1214–1218, 1996.[Abstract]
  25. Mukai Y, Shimokawa H, Matoba T, Kandabashi T, Satoh S, Hiroki J, Kaibuchi K, Takeshita A. Involvement of Rho-kinase in hypertensive vascular disease: a novel therapeutic target in hypertension. Faseb J 15: 1062–1064, 2001.[Free Full Text]
  26. Muller-Brunotte R, Edner M, Malmqvist K, Kahan T. Irbesartan and atenolol improve diastolic function in patients with hypertensive left ventricular hypertrophy. J Hypertens 23: 633–640, 2005.[Web of Science][Medline]
  27. Owan TE, Redfield MM. Epidemiology of diastolic heart failure. Prog Cardiovasc Dis 47: 320–332, 2005.[CrossRef][Web of Science][Medline]
  28. Pardo Mindan FJ, Panizo A. Alterations in the extracellular matrix of the myocardium in essential hypertension. Eur Heart J 14, Suppl J: 12–14, 1993.
  29. Rikitake Y, Oyama N, Wang CY, Noma K, Satoh M, Kim HH, Liao JK. Decreased perivascular fibrosis but not cardiac hypertrophy in ROCK1+/– haploinsufficient mice. Circulation 112: 2959–2965, 2005.[Abstract/Free Full Text]
  30. Satoh S, Ueda Y, Koyanagi M, Kadokami T, Sugano M, Yoshikawa Y, Makino N. Chronic inhibition of Rho kinase blunts the process of left ventricular hypertrophy leading to cardiac contractile dysfunction in hypertension-induced heart failure. J Mol Cell Cardiol 35: 59–70, 2003.[CrossRef][Web of Science][Medline]
  31. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, Gutgesell H, Reichek N, Sahn D, Schnittger I, Silverman NH, Tajik AJ. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 2: 358–367, 1989.[Medline]
  32. See F, Thomas W, Way K, Tzanidis A, Kompa A, Lewis D, Itescu S, Krum H. p38 mitogen-activated protein kinase inhibition improves cardiac function and attenuates left ventricular remodeling following myocardial infarction in the rat. J Am Coll Cardiol 44: 1679–1689, 2004.[Abstract/Free Full Text]
  33. Shimokawa H, Takeshita A. Rho-Kinase is an important therapeutic target in cardiovascular medicine. Arterioscler Thromb Vasc Biol 25: 1767–1775, 2005.[Abstract/Free Full Text]
  34. Simpson P. Stimulation of hypertrophy of cultured neonatal rat heart cells through an alpha 1-adrenergic receptor and induction of beating through an alpha 1- and beta 1-adrenergic receptor interaction. Evidence for independent regulation of growth and beating. Circ Res 56: 884–894, 1985.[Abstract/Free Full Text]
  35. Thomas WG, Brandenburger Y, Autelitano DJ, Pham T, Qian H, Hannan RD. Adenoviral-directed expression of the type 1A angiotensin receptor promotes cardiomyocyte hypertrophy via transactivation of the epidermal growth factor receptor. Circ Res 90: 135–142, 2002.[Abstract/Free Full Text]
  36. Torsoni AS, Fonseca PM, Crosara-Alberto DP, Franchini KG. Early activation of p160ROCK by pressure overload in rat heart. Am J Physiol Cell Physiol 284: C1411–C1419, 2003.[Abstract/Free Full Text]
  37. Tzanidis A, Hannan RD, Thomas WG, Onan D, Autelitano DJ, See F, Kelly DJ, Gilbert RE, Krum H. Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy. Circ Res 93: 246–253, 2003.[Abstract/Free Full Text]
  38. Vasan RS, Larson MG, Benjamin EJ, Evans JC, Reiss CK, Levy D. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol 33: 1948–1955, 1999.[Abstract/Free Full Text]
  39. Wang YX, da Cunha V, Martin-McNulty B, Vincelette J, Li W, Choy DF, Halks-Miller M, Mahmoudi M, Schroeder M, Johns A, Light DR, Dole WP. Inhibition of Rho-kinase by fasudil attenuated angiotensin II-induced cardiac hypertrophy in apolipoprotein E deficient mice. Eur J Pharmacol 512: 215–222, 2005.[CrossRef][Web of Science][Medline]
  40. Woodcock EA, Wang BH, Arthur JF, Lennard A, Matkovich SJ, Du XJ, Brown JH, Hannan RD. Inositol polyphosphate 1-phosphatase is a novel antihypertrophic factor. J Biol Chem 277: 22734–22742, 2002.[Abstract/Free Full Text]
  41. Yamamoto K, Masuyama T, Sakata Y, Nishikawa N, Mano T, Yoshida J, Miwa T, Sugawara M, Yamaguchi Y, Ookawara T, Suzuki K, Hori M. Myocardial stiffness is determined by ventricular fibrosis, but not by compensatory or excessive hypertrophy in hypertensive heart. Cardiovasc Res 55: 76–82, 2002.[Abstract/Free Full Text]
  42. Zhang YM, Bo J, Taffet GE, Chang J, Shi J, Reddy AK, Michael LH, Schneider MD, Entman ML, Schwartz RJ, Wei L. Targeted deletion of ROCK1 protects the heart against pressure overload by inhibiting reactive fibrosis. Faseb J 20: 916–925, 2006.[Abstract/Free Full Text]
  43. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: Part II: causal mechanisms and treatment. Circulation 105: 1503–1508, 2002.[Free Full Text]




This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
294/4/H1804    most recent
01078.2007v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Phrommintikul, A.
Right arrow Articles by Krum, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Phrommintikul, A.
Right arrow Articles by Krum, H.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2008 by the American Physiological Society.